ClinicalTrials.gov
ClinicalTrials.gov Menu

Cyclophosphamide W/or W/Out Rituximab and Peripheral Stem Cell Transplantation in Patients With Recurrent Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00028665
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : June 10, 2010
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
Case Comprehensive Cancer Center

Brief Summary:

RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known if combining rituximab with cyclophosphamide is more effective than cyclophosphamide alone in stimulating peripheral stem cells for transplantation.

PURPOSE: This randomized phase II trial is studying how well giving cyclophosphamide with or without rituximab followed by chemotherapy and peripheral stem cell transplantation works in treating patients with recurrent non-Hodgkin's lymphoma.


Condition or disease Intervention/treatment Phase
Lymphoma Biological: filgrastim Biological: rituximab Drug: carmustine Drug: cisplatin Drug: cyclophosphamide Drug: etoposide Procedure: bone marrow ablation with stem cell support Procedure: peripheral blood stem cell transplantation Radiation: radiation therapy Phase 2

Detailed Description:

OBJECTIVES:

  • Compare the effects of mobilization therapy with or without rituximab on hematopoietic stem cells, B and T lymphocytes, and natural killer cells in patients with advanced or recurrent B-cell non-Hodgkin's lymphoma.
  • Compare the effects of B-lymphocyte purging using concurrent rituximab and mobilization therapy vs a CD34+ cell enrichment device on hematopoietic stem cells, B and T lymphocytes, and natural killer cells in the peripheral blood stem cell (PBSC) infusates.
  • Compare the effect of these purging regimens on tumor cell content of PBSC infusates.
  • Compare the effects of these regimens on myeloid and lymphoid engraftment after high-dose chemotherapy and autologous PBSC infusion in these patients.
  • Compare post-transplantation infection complications in patients treated with these regimens.
  • Compare the response and relapse-free survival of patients treated with these regimens.

OUTLINE: This is a randomized study. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive mobilization therapy comprising rituximab IV over 2-5 hours on days 1, 8, and 15 and cyclophosphamide IV over 3-6 hours on day 16. Beginning 36-48 hours after the completion of cyclophosphamide, patients receive filgrastim (G-CSF) subcutaneously (SC) daily until blood counts recover. Patients then undergo peripheral blood stem cell (PBSC) collection.

After completion of PBSC collection, patients receive high-dose chemotherapy comprising carmustine IV on days -7 to -3 and etoposide IV and cisplatin IV for 3 days during days -7 to -3. Patients may undergo involved-field radiotherapy to active or previously bulky (more than 5 cm) tumors daily for 7-10 days.

Patients receive unmanipulated PBSCs on day 0. Patients receive G-CSF SC daily beginning 4 hours after completion of PBSC infusion and continuing until neutrophil engraftment.

  • Arm II: Patients receive mobilization therapy comprising cyclophosphamide and G-CSF and high-dose chemotherapy comprising carmustine, etoposide, and cisplatin as in arm I. Patients may also undergo involved-field radiotherapy as in arm I. Patients receive CD34 cell-enriched PBSC on day 0 followed by G-CSF as in arm I.

Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 71 patients will be accrued for this study within 2 years.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase II Trial of B-Lymphocyte Purging of Autologous Peripheral Blood Progenitor Cells in Patients With B-Cell Non-Hodgkin's Lymphoma
Study Start Date : June 2000
Actual Primary Completion Date : March 2005


Arm Intervention/treatment
Experimental: Arm I: with rituximab IV Biological: filgrastim
Beginning 36-48 hours after the completion of cyclophosphamide, patients receive filgrastim (G-CSF) subcutaneously (SC) daily until blood counts recover. Patients receive G-CSF SC daily beginning 4 hours after completion of PBSC infusion and continuing until neutrophil engraftment.

Biological: rituximab
rituximab IV over 2-5 hours on days 1, 8, and 15

Drug: carmustine
After completion of PBSC collection, patients receive high-dose chemotherapy comprising carmustine IV on days -7 to -3

Drug: cisplatin
After completion of PBSC collection, cisplatin IV for 3 days during days -7 to -3.

Drug: cyclophosphamide
cyclophosphamide IV over 3-6 hours on day 16.

Drug: etoposide
After completion of PBSC collection, etoposide IV for 3 days during days -7 to -3.

Procedure: bone marrow ablation with stem cell support
Patients then undergo peripheral blood stem cell (PBSC) collection.

Procedure: peripheral blood stem cell transplantation
Arm I: Patients receive unmanipulated PBSCs on day 0. Arm II: Patients receive CD34 cell-enriched PBSC on day 0.

Radiation: radiation therapy
Patients may undergo involved-field radiotherapy to active or previously bulky (more than 5 cm) tumors daily for 7-10 days.

Active Comparator: Arm II: without rituximab IV Biological: filgrastim
Beginning 36-48 hours after the completion of cyclophosphamide, patients receive filgrastim (G-CSF) subcutaneously (SC) daily until blood counts recover. Patients receive G-CSF SC daily beginning 4 hours after completion of PBSC infusion and continuing until neutrophil engraftment.

Drug: carmustine
After completion of PBSC collection, patients receive high-dose chemotherapy comprising carmustine IV on days -7 to -3

Drug: cisplatin
After completion of PBSC collection, cisplatin IV for 3 days during days -7 to -3.

Drug: cyclophosphamide
cyclophosphamide IV over 3-6 hours on day 16.

Drug: etoposide
After completion of PBSC collection, etoposide IV for 3 days during days -7 to -3.

Procedure: bone marrow ablation with stem cell support
Patients then undergo peripheral blood stem cell (PBSC) collection.

Procedure: peripheral blood stem cell transplantation
Arm I: Patients receive unmanipulated PBSCs on day 0. Arm II: Patients receive CD34 cell-enriched PBSC on day 0.

Radiation: radiation therapy
Patients may undergo involved-field radiotherapy to active or previously bulky (more than 5 cm) tumors daily for 7-10 days.




Primary Outcome Measures :
  1. Total CD34 cells [ Time Frame: measured at baseline, at time of harvests, days 42 and 90 after the transplant, and 6 and 12 months after the transplant ]
  2. T and B lymphocyte counts [ Time Frame: measured at baseline, at time of harvests, days 42 and 90 after the transplant, and 6 and 12 months after the transplant ]
  3. Disease response [ Time Frame: measured at 4 weeks after the transplant ]
  4. Engraftment [ Time Frame: measured at days 42 and 90 after the transplant, and 6 and 12 months after the transplant ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   12 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed B-cell non-Hodgkin's lymphoma (NHL)

    • Indolent or aggressive histology
    • No small lymphocytic lymphoma, Burkitt's lymphoma, or small lymphocytic non-Burkitt's lymphoma
  • CD20-positive and/or CD19-positive by immunohistochemistry or flow cytometry
  • Second or greater remission allowed

    • Partial remission, relapse, or refractory disease must have measurable tumor
  • Eligible for high-dose therapy followed by autologous peripheral blood stem cell transplantation
  • No CNS involvement by lymphoma

PATIENT CHARACTERISTICS:

Age:

  • 12 to 65

Performance status:

  • ECOG 0-2

Life expectancy:

  • Not specified

Hematopoietic:

  • Absolute neutrophil count greater than 1,200/mm^3
  • Platelet count greater than 100,000/mm^3

Hepatic:

  • Bilirubin less than 2.0 mg/dL

Renal:

  • Creatinine clearance at least 60 mL/min
  • No renal dysfunction

Cardiovascular:

  • LVEF at least 40%
  • No cardiac dysfunction
  • No myocardial infarction within the past 3 months

Pulmonary:

  • FEV_1 greater than 60%
  • DLCO at least 60% of predicted
  • No pulmonary dysfunction
  • No asthma

Other:

  • HIV negative
  • No significant organ dysfunction
  • No severe comorbid condition
  • No uncontrolled diabetes
  • No severe or active infection
  • Not pregnant or nursing
  • Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

  • See Chemotherapy
  • No prior immunotherapy

Chemotherapy:

  • No prior high-dose chemotherapy with or without peripheral blood stem cell transplantation
  • No more than 3 prior chemotherapy regimens for NHL
  • At least 4 weeks since prior chemotherapy and recovered

Endocrine therapy:

  • Not specified

Radiotherapy:

  • Prior radiotherapy allowed

Surgery:

  • Not specified

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00028665


Locations
United States, Ohio
Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University
Cleveland, Ohio, United States, 44106-7284
Sponsors and Collaborators
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Investigators
Study Chair: Omer N. Koc, MD Case Comprehensive Cancer Center

Responsible Party: Omer Koc, MD, Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT00028665     History of Changes
Other Study ID Numbers: CWRU1499
P30CA043703 ( U.S. NIH Grant/Contract )
CWRU1499 ( Other Identifier: Case Comprehensive Cancer Center )
CWRU-030040
NCI-G01-2040
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: June 10, 2010
Last Verified: June 2010

Keywords provided by Case Comprehensive Cancer Center:
stage III grade 1 follicular lymphoma
stage III grade 2 follicular lymphoma
stage III grade 3 follicular lymphoma
stage III adult diffuse small cleaved cell lymphoma
stage III adult diffuse mixed cell lymphoma
stage III adult diffuse large cell lymphoma
stage III adult immunoblastic large cell lymphoma
stage III adult lymphoblastic lymphoma
stage IV grade 1 follicular lymphoma
stage IV grade 2 follicular lymphoma
stage IV grade 3 follicular lymphoma
stage IV adult diffuse small cleaved cell lymphoma
stage IV adult diffuse mixed cell lymphoma
stage IV adult diffuse large cell lymphoma
stage IV adult immunoblastic large cell lymphoma
stage IV adult lymphoblastic lymphoma
recurrent grade 1 follicular lymphoma
recurrent grade 2 follicular lymphoma
recurrent grade 3 follicular lymphoma
recurrent adult diffuse small cleaved cell lymphoma
recurrent adult diffuse mixed cell lymphoma
recurrent adult diffuse large cell lymphoma
recurrent adult immunoblastic large cell lymphoma
stage III mantle cell lymphoma
stage IV mantle cell lymphoma
recurrent mantle cell lymphoma

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Etoposide phosphate
Cisplatin
Cyclophosphamide
Rituximab
Etoposide
Carmustine
Lenograstim
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Antineoplastic Agents, Phytogenic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Adjuvants, Immunologic